Karyopharm Therapeutics Inc. (KPTI)
Chart Events
Performance Outlook
| Previous Close | 8.37 |
| Open | 8.32 |
| Bid | 8.30 x 2900 |
| Ask | 8.55 x 3100 |
| Day's Range | 8.27 - 8.46 |
| 52 Week Range | 7.78 - 18.00 |
| Volume | 696,910 |
| Avg. Volume | 1,435,385 |
| Market Cap | 625.521M |
| Beta (5Y Monthly) | 0.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Analysts Estimate Karyopharm Therapeutics (KPTI) to Report a Decline in Earnings: What to Look Out for
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Karyopharm Therapeutics Inc (KPTI): Are Hedge Funds Right About This Stock?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]
- Benzinga
Karyopharm Stock Is Trading Higher On Updated Eltanexor Data In Patients With Blood Disorder
Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced updated data from Phase 1/2 trial of eltanexor (ATG-016) for patients with hypomethylating agent (HMA) refractory myelodysplastic syndrome (MDS). Data were presented at the 2021 American Society of Clinical Oncology Annual Meeting. Of the 15 patients evaluable for efficacy, 7 (47%) had marrow complete response (mCR), and 5 (33%) had stable disease (SD) for a total disease control rate of 80%. In the 10 mg cohort (n=5), all patients derived cli
